search
Back to results

Effects of Caffeine on Anxiety, Emotional Processing, Approach-avoidance Behavior, and Interoception in Panic Disorder

Primary Purpose

Panic Disorder, Healthy

Status
Completed
Phase
Not Applicable
Locations
Sweden
Study Type
Interventional
Intervention
Caffeine
Placebo
Sponsored by
Uppsala University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Panic Disorder

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

Panic disorder group: Primary diagnosis of panic disorder.

Healthy control group: No current or history of psychiatric disorders.

All participants (Panic disorder and healthy): Weekly caffeine consumption ≤ 300 mg.

Exclusion Criteria:

History of severe psychiatric disorder (e.g. schizophrenia). Somatic or neurological conditions (e.g. hypertension and heart condition). Ongoing treatment with psychotropic medication or treatment with psychotropic medication which has been discontinued within 2 months. Other ongoing treatments that may confound the results. Current drug or alcohol abuse/dependency. Habitual nicotine use. Uncorrected visual or hearing impairment. Pregnancy.

Sites / Locations

  • Uppsala university, Department of Medical Sciences, Psychiatry

Arms of the Study

Arm 1

Arm 2

Arm Type

Other

Other

Arm Label

Panic disorder

Healthy controls

Arm Description

Participants will be randomized to start with either the caffeine condition or placebo condition. Participants will complete session 2 with the other condition (condition not allocated to in session 1).

Participants will be randomized to start with either the caffeine condition or placebo condition. Participants will complete session 2 with the other condition (condition not allocated to in session 1).

Outcomes

Primary Outcome Measures

Self-reported anxiety
Anxiety will be assessed before capsule (caffeine/placebo) intake, 30 minutes after intake during rest, and after each task with self-reported ratings on a scale from 0-100 (0=no anxiety - 100=extreme anxiety).
Self-reported anxiety
Anxiety will be assessed before capsule (caffeine/placebo) intake, 30 minutes after intake during rest, and after each task with self-reported ratings on a scale from 0-100 (0=no anxiety - 100=extreme anxiety).

Secondary Outcome Measures

Self-reported emotions
Self-reported emotions (fear, bodily discomfort, negative feelings and positive feelings) will be assessed before capsule (caffeine/placebo) intake, 30 minutes after intake during rest, and after each task with self-reported ratings on a scale from 0-100 (0=none - 100=extreme).
Self-reported emotions
Self-reported emotions (fear, bodily discomfort, negative feelings and positive feelings) will be assessed before capsule (caffeine/placebo) intake, 30 minutes after intake during rest, and after each task with self-reported ratings on a scale from 0-100 (0=none - 100=extreme).
Skin conductance responses (SCR)
SCR:s will be used to assess emotional reactivity at the physiological level to emotional stimuli vs neutral stimuli (faces).
Skin conductance responses (SCR)
SCR:s will be used to assess emotional reactivity at the physiological level to emotional stimuli vs neutral stimuli (faces).
Approach-avoidance behavior
Approach-avoidance behavior will be assessed through an approach-avoidance incentive conflict task.
Approach-avoidance behavior
Approach-avoidance behavior will be assessed through an approach-avoidance incentive conflict task.
Effort-allocation
Effort-allocation for rewards will be assessed using an effort-allocation task.
Effort-allocation
Effort-allocation for rewards will be assessed using an effort-allocation task.
Occurrence of panic attack
The occurrence of a panic attacks will be assessed according to the Diagnostical Statistical Manual (DSM-5) criteria for panic attacks and will be coded dichotomous as "Present" or "Not present".
Occurrence of panic attack
The occurrence of a panic attacks will be assessed according to the Diagnostical Statistical Manual (DSM-5) criteria for panic attacks and will be coded dichotomous as "Present" or "Not present".
Panic symptoms
Panic symptoms will be assessed by counting the number of DSM-5- panic attack symptoms reported by the participant.
Panic symptoms
Panic symptoms will be assessed by counting the number of DSM-5- panic attack symptoms reported by the participant.
Attention to interoceptive stimuli
Attention to interoceptive stimuli will be assessed using self-reported ratings on a scale from 0-100 (0=no attention - 100= full attention). Interoceptive stimuli are defined as bodily sensation such as pulse and respiration.
Attention to interoceptive stimuli
Attention to interoceptive stimuli will be assessed using self-reported ratings on a scale from 0-100 (0=no attention - 100= full attention). Interoceptive stimuli are defined as bodily sensation such as pulse and respiration.
Anxiety associated with attention to interoceptive stimuli
Self-reported ratings of anxiety associated with attention to interoceptive stimuli (bodily sensation such as pulse and respiration) will be assessed using self reported ratings on a scale from (0= no anxiety - 100 = extreme anxiety)
Anxiety associated with attention to interoceptive stimuli
Self-reported ratings of anxiety associated with attention to interoceptive stimuli (bodily sensation such as pulse and respiration) will be assessed using self reported ratings on a scale from (0= no anxiety - 100 = extreme anxiety)

Full Information

First Posted
January 26, 2022
Last Updated
April 14, 2023
Sponsor
Uppsala University
search

1. Study Identification

Unique Protocol Identification Number
NCT05261594
Brief Title
Effects of Caffeine on Anxiety, Emotional Processing, Approach-avoidance Behavior, and Interoception in Panic Disorder
Official Title
Effects of Caffeine on Anxiety, Emotional Processing, Approach-avoidance Behavior, and Interoception in Panic Disorder - a Double Blind Randomized Controlled Study
Study Type
Interventional

2. Study Status

Record Verification Date
April 2023
Overall Recruitment Status
Completed
Study Start Date
March 16, 2022 (Actual)
Primary Completion Date
March 19, 2023 (Actual)
Study Completion Date
March 19, 2023 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Uppsala University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The current study is a placebo-controlled, double-blind, randomized controlled study using a cross-over design, including participants with Panic disorder and healthy controls. The study's primary aim is to investigate the effects of caffeine (vs placebo) on self-reported anxiety and its impact on emotional reactivity and goal-directed behavior in individuals with Panic disorder (vs healthy controls). Emotional reactivity will be measured with self-reported emotions and skin conductance responses. Caffeine-induced effects on goal-directed behavior will be assessed using an approach-avoidance conflict paradigm and an effort-allocation task. The occurrence of panic attacks and panic-related symptoms will also be measured. Furthermore, the link between a genotype of ADORA2A (rs5751876 T/T) previously associated with caffeine-induced anxiety, and the anxiogenic effects of caffeine will also be explored. In addition, caffeine-induced changes in attention to interoceptive stimuli (bodily sensation such as pulse and respiration) and anxiety elicited by attention to interoceptive stimuli will be explored. A secondary aim is to examine the potential caffeine-induced effects and the impact of genetic variation in healthy participants (caffeine vs placebo).
Detailed Description
Hypotheses Self-reported anxiety during resting state Participants with Panic disorder will report higher resting-state levels of anxiety and negative emotions during the caffeine condition vs the placebo condition. Participants with Panic disorder will report higher resting-state levels of caffeine-induced (caffeine > placebo) anxiety and negative emotions compared to healthy subjects. Panic attacks The occurrence of panic attacks and panic-related symptoms will be higher among participants with Panic disorder than in healthy controls in both conditions (caffeine and placebo). Genetic variation Carriers of adenosine A2A receptor (i.e., ADORA2A) polymorphism (rs5751876 T/T) will report higher levels of caffeine-induced (caffeine >placebo) anxiety and negative emotions, in both individuals with Panic disorder and healthy participants. Attention to interoceptive stimuli and associated anxiety Participants with Panic disorder will report higher levels of attention towards interoceptive stimuli in the caffeine condition (vs placebo). Participants with Panic disorder will report higher levels of self-reported anxiety associated with experiencing interoceptive stimuli during the caffeine condition (vs placebo). Participants with Panic disorder will report higher levels of self-reported attention to interoceptive stimuli and anxiety associated with experiencing interoceptive stimuli compared to healthy participants, both in general (placebo condition) and after caffeine intake (caffeine vs placebo). Exploratory research questions Analyses of emotional reactivity, the approach-avoidance conflict task, and the effort-allocation task will be exploratory without directed hypotheses, due to lack of previous research on the effects of caffeine in patients with Panic disorder on these tasks. We will also conduct exploratory analyses to explore if 150 mg of caffeine (vs placebo) affect self-reported levels of positive emotions in patients with Panic disorder and healthy controls.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Panic Disorder, Healthy

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Model Description
The study entails two sessions and uses a crossover design. Participants will be randomized to start with either the caffeine condition or the placebo condition. Participants will complete the second session with the other condition (the condition not allocated to in session 1). The study includes two arms: (a) participants with Panic disorder (estimated n=50; actual n=30) and (b) healthy controls (estimated n=50; actual n=53). Both arms (Panic disorder and healthy controls) will complete both conditions (caffeine and placebo condition) in randomized order.
Masking
ParticipantInvestigator
Masking Description
Double blind
Allocation
Randomized
Enrollment
83 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Panic disorder
Arm Type
Other
Arm Description
Participants will be randomized to start with either the caffeine condition or placebo condition. Participants will complete session 2 with the other condition (condition not allocated to in session 1).
Arm Title
Healthy controls
Arm Type
Other
Arm Description
Participants will be randomized to start with either the caffeine condition or placebo condition. Participants will complete session 2 with the other condition (condition not allocated to in session 1).
Intervention Type
Dietary Supplement
Intervention Name(s)
Caffeine
Intervention Description
Caffeine capsule 150 mg, oral intake
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo capsule, oral intake
Primary Outcome Measure Information:
Title
Self-reported anxiety
Description
Anxiety will be assessed before capsule (caffeine/placebo) intake, 30 minutes after intake during rest, and after each task with self-reported ratings on a scale from 0-100 (0=no anxiety - 100=extreme anxiety).
Time Frame
Session 1 (day 1)
Title
Self-reported anxiety
Description
Anxiety will be assessed before capsule (caffeine/placebo) intake, 30 minutes after intake during rest, and after each task with self-reported ratings on a scale from 0-100 (0=no anxiety - 100=extreme anxiety).
Time Frame
Session 2 (minimum of 36 hours after Session 1 (day 1) maximum of 14 days after Session 1 (day 1))
Secondary Outcome Measure Information:
Title
Self-reported emotions
Description
Self-reported emotions (fear, bodily discomfort, negative feelings and positive feelings) will be assessed before capsule (caffeine/placebo) intake, 30 minutes after intake during rest, and after each task with self-reported ratings on a scale from 0-100 (0=none - 100=extreme).
Time Frame
Session 1 (day 1)
Title
Self-reported emotions
Description
Self-reported emotions (fear, bodily discomfort, negative feelings and positive feelings) will be assessed before capsule (caffeine/placebo) intake, 30 minutes after intake during rest, and after each task with self-reported ratings on a scale from 0-100 (0=none - 100=extreme).
Time Frame
Session 2 (minimum of 36 hours after Session 1 (day 1) maximum of 14 days after Session 1 (day 1))
Title
Skin conductance responses (SCR)
Description
SCR:s will be used to assess emotional reactivity at the physiological level to emotional stimuli vs neutral stimuli (faces).
Time Frame
Session 1 (day 1)
Title
Skin conductance responses (SCR)
Description
SCR:s will be used to assess emotional reactivity at the physiological level to emotional stimuli vs neutral stimuli (faces).
Time Frame
Session 2 (minimum of 36 hours after Session 1 (day 1) maximum of 14 days after Session 1 (day 1))
Title
Approach-avoidance behavior
Description
Approach-avoidance behavior will be assessed through an approach-avoidance incentive conflict task.
Time Frame
Session 1 (day 1)
Title
Approach-avoidance behavior
Description
Approach-avoidance behavior will be assessed through an approach-avoidance incentive conflict task.
Time Frame
Session 2 (minimum of 36 hours after Session 1 (day 1) maximum of 14 days after Session 1 (day 1))
Title
Effort-allocation
Description
Effort-allocation for rewards will be assessed using an effort-allocation task.
Time Frame
Session 1 (day 1)
Title
Effort-allocation
Description
Effort-allocation for rewards will be assessed using an effort-allocation task.
Time Frame
Session 2 (minimum of 36 hours after Session 1 (day 1) maximum of 14 days after Session 1 (day 1))
Title
Occurrence of panic attack
Description
The occurrence of a panic attacks will be assessed according to the Diagnostical Statistical Manual (DSM-5) criteria for panic attacks and will be coded dichotomous as "Present" or "Not present".
Time Frame
Session 1 (day 1)
Title
Occurrence of panic attack
Description
The occurrence of a panic attacks will be assessed according to the Diagnostical Statistical Manual (DSM-5) criteria for panic attacks and will be coded dichotomous as "Present" or "Not present".
Time Frame
Session 2 (minimum of 36 hours after Session 1 (day 1) maximum of 14 days after Session 1 (day 1))
Title
Panic symptoms
Description
Panic symptoms will be assessed by counting the number of DSM-5- panic attack symptoms reported by the participant.
Time Frame
Session 1 (day 1)
Title
Panic symptoms
Description
Panic symptoms will be assessed by counting the number of DSM-5- panic attack symptoms reported by the participant.
Time Frame
Session 2 (minimum of 36 hours after Session 1 (day 1) maximum of 14 days after Session 1 (day 1))
Title
Attention to interoceptive stimuli
Description
Attention to interoceptive stimuli will be assessed using self-reported ratings on a scale from 0-100 (0=no attention - 100= full attention). Interoceptive stimuli are defined as bodily sensation such as pulse and respiration.
Time Frame
Session 1 (day 1)
Title
Attention to interoceptive stimuli
Description
Attention to interoceptive stimuli will be assessed using self-reported ratings on a scale from 0-100 (0=no attention - 100= full attention). Interoceptive stimuli are defined as bodily sensation such as pulse and respiration.
Time Frame
Session 2 (minimum of 36 hours after Session 1 (day 1) maximum of 14 days after Session 1 (day 1))
Title
Anxiety associated with attention to interoceptive stimuli
Description
Self-reported ratings of anxiety associated with attention to interoceptive stimuli (bodily sensation such as pulse and respiration) will be assessed using self reported ratings on a scale from (0= no anxiety - 100 = extreme anxiety)
Time Frame
Session 1 (day 1)
Title
Anxiety associated with attention to interoceptive stimuli
Description
Self-reported ratings of anxiety associated with attention to interoceptive stimuli (bodily sensation such as pulse and respiration) will be assessed using self reported ratings on a scale from (0= no anxiety - 100 = extreme anxiety)
Time Frame
Session 2 (minimum of 36 hours after Session 1 (day 1) maximum of 14 days after Session 1 (day 1))
Other Pre-specified Outcome Measures:
Title
Expectancy ratings
Description
Participants will be asked to report if they believed that they received placebo or caffeine and how certain they are on a scale from 0-100%
Time Frame
Session 1 (day 1)
Title
Expectancy ratings
Description
Participants will be asked to report if they believed that they received placebo or caffeine and how certain they are on a scale from 0-100%
Time Frame
Session 2 (minimum of 36 hours after Session 1 (day 1) maximum of 14 days after Session 1 (day 1))
Title
Panic Disorder Severity Scale (PDSS)
Description
PDSS is a self-reported questionnaire that assesses the severity of Panic disorder; range 0-28, higher scores indicating more severe symptoms
Time Frame
1-7 days prior to session 1 (internet)
Title
Body Sensations Questionnaire (BSQ)
Description
BSQ assesses body sensations present during aversive situations; range 17-85, higher scores indicating higher levels of body sensations
Time Frame
1-7 days prior to session 1 (via internet)
Title
Multidimensional Assessment of Interoceptive Awareness (MAIA-2)
Description
MAIA-2 is an 8-scale state-trait questionnaire with 37 items to measure multiple dimensions of interoception by self-report. The score of each scale is the the average of the items on each scale. Higher mean scores indicate higher levels on of the measured dimensions (Noticing, Not-Distracting, Not-Worrying, Attention Regulation, Emotional Awareness,Self-Regulation, Body Listening, and Trust) on a scale from 0-5 (0=never- 5=always), respectively
Time Frame
1-7 days prior to session 1 (via internet)
Title
Anxiety Sensitivity Index (ASI)
Description
ASI assesses anxiety sensitivity; range 0-64, higher scores indicating higher anxiety sensitivity
Time Frame
1-7 days prior to session 1 (via internet)
Title
Spielberger State-Trait Anxiety Inventory (STAI-T)
Description
STAI-T is a self-rated questionnaire assessing trait anxiety; range 20-80, higher scores represent higher levels of trait anxiety
Time Frame
1-7 days prior to session 1 (via internet)
Title
Caffeine Expectancy Questionnaire (CaffEQ)
Description
CaffEQ is a self-rated questionnaire that assesses expected effect of caffeine intake.
Time Frame
1-7 days prior to session 1 (via internet)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Panic disorder group: Primary diagnosis of panic disorder. Healthy control group: No current or history of psychiatric disorders. All participants (Panic disorder and healthy): Weekly caffeine consumption ≤ 300 mg. Exclusion Criteria: History of severe psychiatric disorder (e.g. schizophrenia). Somatic or neurological conditions (e.g. hypertension and heart condition). Ongoing treatment with psychotropic medication or treatment with psychotropic medication which has been discontinued within 2 months. Other ongoing treatments that may confound the results. Current drug or alcohol abuse/dependency. Habitual nicotine use. Uncorrected visual or hearing impairment. Pregnancy.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Andreas Frick, PhD
Organizational Affiliation
Uppsala University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Uppsala university, Department of Medical Sciences, Psychiatry
City
Uppsala
ZIP/Postal Code
75185
Country
Sweden

12. IPD Sharing Statement

Learn more about this trial

Effects of Caffeine on Anxiety, Emotional Processing, Approach-avoidance Behavior, and Interoception in Panic Disorder

We'll reach out to this number within 24 hrs